Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg initiates trio of UK industrials with 'buy' ratings amid sector underperformance

(Sharecast News) - Analysts at Berenberg initiated coverage on a number of UK capital goods and industrial engineering firms on Wednesday, noting that UK industrials have underperformed the market 11.8% year-to-date, with macroeconomic uncertainty and tariffs not helping matters. Berenberg said it was looking for equity stories where stock-specific factors can support better investor returns, leading it to launch coverage of three stocks where there has been a change in recent periods that could provide inflexion points to both the businesses and their respective share price.

Berenberg started Strix with a 'buy' rating and a 90p target price, arguing that the market was undervaluing the group's resilient fundamentals and cash-generative profile. It said Strix trades at just a 5.9x FY25 price-to-earnings ratio - despite sector-leading underlying margins of 18% and near-100% cash conversion. It also believes investors have been overly focused on transitory headwinds, including the slowing performance of its Billi acquisition, stagnation in its controls division, and a legacy debt pile.

The German bank also sees scope for buybacks given the depressed share price, but notes that management's track record in acquisitions supports a longer-term growth strategy. With a forecast free cash flow yield of 16.9% in FY26, Berenberg considers Strix a compelling re-entry point for investors.

Berenberg also picked up coverage of Trifast with a 'buy' rating and a 130p price target, with the analysts highlighting the company's multi-year turnaround under new management and stating that it sees further upside from operational improvements and self-help initiatives, while Zotefoams was also started at 'buy' with a 540p price target, citing a strategic pivot under new chief executive Ronan Cox and a materially undervalued growth opportunity.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.